Gyre Therapeutics (GYRE) Loans and Notes Receivables (2022 - 2025)
Historic Loans and Notes Receivables for Gyre Therapeutics (GYRE) over the last 4 years, with Q3 2025 value amounting to $693000.0.
- Gyre Therapeutics' Loans and Notes Receivables rose 66153.85% to $693000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $693000.0, marking a year-over-year increase of 66153.85%. This contributed to the annual value of $4.4 million for FY2024, which is 102416.45% up from last year.
- Gyre Therapeutics' Loans and Notes Receivables amounted to $693000.0 in Q3 2025, which was up 66153.85% from $499000.0 recorded in Q2 2025.
- Over the past 5 years, Gyre Therapeutics' Loans and Notes Receivables peaked at $4.4 million during Q4 2024, and registered a low of $91000.0 during Q3 2024.
- Its 4-year average for Loans and Notes Receivables is $1.2 million, with a median of $499000.0 in 2025.
- Its Loans and Notes Receivables has fluctuated over the past 5 years, first tumbled by 7444.15% in 2023, then skyrocketed by 102416.45% in 2024.
- Over the past 4 years, Gyre Therapeutics' Loans and Notes Receivables (Quarter) stood at $1.5 million in 2022, then crashed by 74.44% to $389000.0 in 2023, then skyrocketed by 1024.16% to $4.4 million in 2024, then plummeted by 84.15% to $693000.0 in 2025.
- Its Loans and Notes Receivables was $693000.0 in Q3 2025, compared to $499000.0 in Q2 2025 and $2.1 million in Q1 2025.